Search Results - "Mamonkin, M."

CAR T-cell therapy: Balance of efficacy and safety by Kulemzin, S. V., Kuznetsova, V. V., Mamonkin, M., Taranin, A. V., Gorchakov, A. A.

“…Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged…”
Get full text

Engineering Chimeric Antigen Receptors by Kulemzin, S V, Kuznetsova, V V, Mamonkin, M, Taranin, A V, Gorchakov, A A

“…Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high…”
Get full text

Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling by Gomes da Silva, D, Mukherjee, M, Madhuwanti, S, Dakhova, O, Liu, H, Grilley, B, Gee, A, Neelapu, S.S, Rooney, C, Heslop, H, Savoldo, B, Dotti, G, Brenner, M, Mamonkin, M, Ramos, C.A

Get full text

Immunotherapy: MECHANISMS REGULATING THE RESISTANCE OF NORMAL T-CELLS TO CD5 CAR-MEDIATED CYTOTOXICITY by Ma, R., Woods, M.L., Chaumette, A., Popat, D., Carisey, A., Brenner, M., Mamonkin, M.

Get full text

Immunotherapy: SIGNALING DOMAINS, 41BB AND CD28, MEDIATE DISTINCT MOLECULAR DYNAMICS AT THE IMMUNE SYNAPSE THAT INFLUENCE CAR T CELL KILLING BEHAVIOR by Gad, A.Z., Morris, J.S., Godret-Miertschin, L., Montalvo, M.J., Fousek, K., Saeedi, A., Levental, K., Mamonkin, M., Carisey, A., Joseph, S., Hegde, M., Varadarajan, N., Levental, I., Mukherjee, M., Ahmed, N.

Get full text

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy by Williams, Alan M, Hayama, Ken, Pan, Yijia, Groff, Brian, Mbofung, Rina M, Fong, Lauren, Brookhouser, Nicholas, Mandefro, Berhan, Abujarour, Ramzey, Lee, Tom, Hammer, Quirin, Malmberg, Karl-Johan, Mamonkin, Maksim, Bjordahl, Ryan, Goodridge, Jode P, Valamehr, Bahram

“…Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematologic malignancies, however, logistical complexities associated…”
Get full text

Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors by Muhsen, I.N., Steffin, D., Ahmed, N., Hegde, M., Dakhova, O., Wang, T., Wu, M., Gottschalk, S., Whittle, S., Lulla, P., Mamonkin, M., Omer, B., Rouce, R.H., Heczey, A., Metelitsa, L., Hill, L., Ramos, C.A., Rooney, C., Brenner, M., Heslop, H.

Get full text

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy by Williams, AM, Hayama, K, Pan, YJ, Groff, B, Mbofung, R, Fong, L, Brookhouser, N, Mandefro, B, Abujarour, R, Lee, T, Hammer, Q, Malmberg, KJ, Mamonkin, M, Bjordahl, R, Goodridge, J, Valamehr, B

Get full text

6 - Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling by Gomes da Silva, D., Mukherjee, M., Madhuwanti, S., Dakhova, O., Liu, H., Grilley, B., Gee, A., Neelapu, S.S., Rooney, C., Heslop, H., Savoldo, B., Dotti, G., Brenner, M., Mamonkin, M., Ramos, C.A.

Get full text